This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

phamide — 25mg, 50mg tabs 1−5mg/kg/day. 500mg, 1g, 2g pwd for IV inj after reconstitution 40−50mg/kg in divided doses over 2−5 days or 10−15mg/kg every 7−10 days or 3−5mg/kg twice ...

Checkpoint inhibitors are a type of immunotherapy. These drugs block different proteins called checkpoint proteins that stop the immune system from attacking the cancer cells. They are a treatment for ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is ...